GENETAC
Live / Registered — Registered (as of 10 Dec 2024)
What this means for you
Registered since 10 Dec 2024. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 10 Dec 2030: the §8 declaration of use).
Record
- Serial number
- 90263391
- Registration number
- 7599711
- Mark type
- Word mark
- Filed
- 19 Oct 2020
- Published for opposition
- 04 May 2021
- Registered
- 10 Dec 2024
- Next maintenance filing
- §8 declaration of use, due by 10 Dec 2030 (grace period to 10 Jun 2031)
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; therapeutic pharmaceuticals for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; small molecule therapies for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation, all of the foregoing related to therapies that target nucleic acids and modulate gene expression
- Class 042 — Scientific and technological services: pharmaceutical research and products development for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; research and development of therapeutics for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; research and development in the field of small molecule therapeutics; scientific research for medical purposes in the field of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; medical and scientific research in the field of pharmaceuticals, all of the foregoing related to therapies that target nucleic acids and modulate gene expression
Owner
- Design Therapeutics, Inc., Carlsbad, CA, US
- Design Therapeutics, Inc., Carlsbad, CA, US
- Design Therapeutics, Inc., Carlsbad, CA, US
Board proceedings on this mark
- Opposition No. 91272599 — Genentech, Inc. v. Design Therapeutics, Inc., filed 28 Oct 2021 (Terminated)
- Extension of Time to Oppose No. 90263391 — Genentech, Inc. v. Design Therapeutics, Inc., filed 20 May 2021 (Terminated)
Prosecution history
- 10 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 18 Nov 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 18 Nov 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 12 Nov 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 10 Sept 2024 — USE AMENDMENT FILED
- 12 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 10 Sept 2024 — TEAS STATEMENT OF USE RECEIVED
- 30 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Apr 2024 — SOU EXTENSION 2 GRANTED
- 29 Apr 2024 — SOU EXTENSION 2 FILED
- 29 Apr 2024 — SOU TEAS EXTENSION RECEIVED
- 24 Oct 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Oct 2023 — SOU EXTENSION 1 GRANTED
- 20 Oct 2023 — SOU EXTENSION 1 FILED